Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCORPIO-PEP: S-217622 for Prevention of Symptomatic COVID-19 in Household Contacts
NCT05897541Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jun 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of ensitrelvir in coronavirus disease 2019 (COVID-19), sponsored by Shionogi & Co., Ltd.. Started Jun 2023; status: completed.
02
Drugs
ensitrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05897541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05897541.